EFPIA - European Federation of Pharmaceutical Industries and Associations

#Imagine if Europe found the treatment to slow Alzheimer’s progression, produced the first vaccine for brain cancer or medicines that could transform the lives of patients with chronic disease. Now we've imagined. Let's take action: https://shorturl.at/cCGVZ #WeWontRest

How can EMA assessment outputs support regulatory reliance pathways, helping to streamline the approval of variations efficiently and sustainably? Join us on 3 April 2025 for a joint webinar, organised in partnership between European Medicines Agency and EFPIA, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs, EuropaBio - the European Association for Bioindustries, IFPMA and Vaccines Europe focused on the current and future EMA post-authorization framework – including variations and renewals. Register here: https://lnkd.in/daS9nRmn #WeWontRest

EFPIA - European Federation of Pharmaceutical Industries and Associations

🌟 This week the 2025-version of the #Comparator Report on Cancer in Europe was launched. Bengt Jönsson and Nils Wilking founded this report series 20 years ago. Since then, it has become part of IHE - The Swedish Institute for Health Economics’s legacy and a European reference for data and statistics on cancer.   💡 The report analyzes and compares the cancer situation in Europe. It provides a comprehensive view of the development of cancer between 1995 and 2023. It highlights differences between countries in terms of the disease #burden, #costs, and patient #access to new cancer medicines and molecular diagnostics. It also describes the advances in the medical field and discusses policy issues of how to bridge #inequalities in access to medicines across countries.   🎤 Nils Wilking and Thomas Hofmarcher presented and discussed the report last wednesday at the event “Cancer Care 2030: From policy ambition to impact” hosted by EFPIA - European Federation of Pharmaceutical Industries and Associations in Brussels! Participating organizations include European Commission, Greek Ministry of Health, Zorginstituut Nederland, NHS, Karolinska Institutet, University of Glasgow, Union for International Cancer Control (UICC), ESMO - European Society for Medical Oncology, European Cancer Organisation, All.Can International, Youth Cancer Europe , Cancer Patients Europe - CPE, Melanoma Patient Network Europe, Mamma Mia!, MSD Europe, Novartis, MENARINI Group, GSK AstraZeneca Pfizer, Astellas Pharma.   👉 Download the report: https://lnkd.in/dWBMFYyY

As #DIAEurope2025 comes to its end, here are a couple key messages captured from the #EURegulatoryTownhall - #Driving #Innovation in EU Healthcare: A Call for #Smarter #Regulation 🧬 To foster innovation in Europe, we must modernize our regulatory framework. That means simplifying processes, enhancing expertise-driven assessments, and ensuring real-world data (RWD/RWE) is fully integrated into drug development and decision making. 🪬Regulation should be a partner in innovation, not a barrier—early dialogue, scientific advice, and collaboration are key. We must balance safety and access, embracing regulatory excellence while avoiding unnecessary delays. AI is already transforming dossier writing—how can it do the same for assessments? We need to better leverage Europe’s data leadership for interoperable solutions. 💡The EU must remain a global leader in life sciences. Let’s make Europe the place where innovation thrives—not where it gets stuck. #Innovation #RegulatoryExcellence #LifeSciences #PatientCentric Virginia Acha, EFPIA - European Federation of Pharmaceutical Industries and Associations European Medicines Agency Emer Cooke #Heads of Medicine Agencies #HMA María Jesús Lamas Díaz European Commission European Patients' Forum

The new IHE Cancer Comparator report 2025 is now available, offering a comprehensive overview of #cancer outcomes across #Europe. Here are the main findings: 🔷 Survival rates: 12 countries experienced a decline in cancer deaths per 100,000 inhabitants between 1995 and 2022. Several cancer types have now a five-year survival rate exceeding 90% in the best-performing countries. 🔷Breakthrough treatments: The EMA has approved almost 200 new cancer medicines since 1995. 🔷Health spending share: Cancer is a disease where the health spending share (7%) remains below the share of the disease burden that it causes (23% of deaths, 17% of DALYs) in Europe. 🔷Embracing innovation: Uptake of new cancer medicines is uneven – Austria, Switzerland and France lead the way; Latvia, Poland, Estonia and Slovakia have the lowest uptake. 🔷Data saves lives: A lack of real-world data on treatment & survivals hampers evidence-based policymaking; just 15 of 31 European countries publish comprehensive five-year survival rates. 🔷Biomarker bottlenecks: molecular diagnostics are vital to precision medicine, but access is limited, especially in Central and Eastern European countries. 🔷Spending differences: cancer spending is linked to better survival, but varies from <€150 per capita in Hungary, Croatia, Romania, Latvia and Bulgaria to >€400 in Germany and Switzerland. Read more: https://lnkd.in/dvmEip7M #WeWontRest

Nonostante il #cancro diventerà la principale causa di morte nell'European Union entro il 2035, il numero di decessi è rimasto stabile dal 2008 e in 12 Paesi UE la #mortalità è in calo. Il report dell’EFPIA - European Federation of Pharmaceutical Industries and Associations https://lnkd.in/dVmgQc9A #oncologia #statistiche Cristoforo Zervos

🎗️ CPE was at Cancer Care 2030: Policy into Impact for Patients   CPE spoke at the Cancer Care 2030 high-level event in Brussels organised by EFPIA - European Federation of Pharmaceutical Industries and Associations, bringing together key stakeholders to discuss the future of oncology in Europe. With cancer cases rising and access to innovation facing significant delays, urgent action is needed to turn policy ambition into real impact for patients.   Our CEO, Antonella Cardone, spoke on the panel "Redesigning Sustainable and Efficient Cancer Care Now", emphasising the importance of a patient-centred ecosystem to reduce waste in cancer care, enhance innovation in prevention and diagnostics, accelerate time to access to innovation across Europe.   Despite major advancements in science and policy, challenges remain. That’s why CPE continues to advocate for pragmatic and agile regulatory systems that, while protecting the safety of the patients, do not delay equitable access across Europe.💜💪   #CancerCare2030 #CancerPatientsEurope #PatientVoice #HealthcareInnovation #CancerPolicy #AccessToCare Katriona Brooksbank Robert Day Eduardo Pisani Yannick R. European CommissionEuropean Parliament

It was great to discuss earlier this week with MEP Stine Bosse, Dirk Van den Steen, and Laura Batchelor at the British Chamber of Commerce | EU & Belgium event on how the pharmaceutical and biotech sectors are contributing to strengthen EU competitiveness. Closing Europe’s innovation gap is a key priority for Commission President Ursula von der Leyen. The soon-to-be-proposed Strategy for European Life Sciences and Biotech Act could be a catalyst. Contributing to this discussion, last year, EFPIA - European Federation of Pharmaceutical Industries and Associations published our building blocks for a competitive life sciences sector in Europe. 1.    Greater policy coherence, overseen by an EU Office for Life Sciences 2.    Having an EU ecosystem that allows transforming ideas into innovation 3.    Developing Europe as globally competitive location for researching and manufacturing new technologies 4.    Delivering for society and economy through investing in health 5.    Securing Europe’s place as globally resilient biopharma player Find out more here: https://lnkd.in/eRZhuKEY.